Pelizaeus-Merzbacher Disease

Genetic MONDO:0010714 Pathograph 11 Leukodystrophy X-linked Recessive Disorder

Pelizaeus-Merzbacher disease (PMD) is an X-linked recessive hypomyelinating leukodystrophy caused by mutations in the PLP1 gene encoding proteolipid protein 1, the major structural protein of central nervous system myelin. PLP1 mutations lead to defective myelination through various mechanisms including protein misfolding, endoplasmic reticulum stress, oligodendrocyte apoptosis, and gene dosage effects. Clinical features include nystagmus, hypotonia, spasticity, ataxia, intellectual disability, and progressive motor deterioration. PMD is classified into connatal (severe), classic, and transitional forms based on age of onset and severity.

0
Mappings
0
Definitions
1
Inheritance
7
Pathophysiology
0
Histopathology
15
Phenotypes
11
Pathograph
1
Genes
4
Treatments
4
Subtypes
0
Differentials
0
Datasets
1
Trials
0
Models
🏷

Classifications

Harrison's Chapter
nervous system disorder demyelinating disease hereditary disease
👪

Inheritance

1
X-linked Recessive
The PLP1 gene is located on chromosome Xq22.2. Most affected individuals are males. Carrier females may show mild neurological signs.
Expressivity: VARIABLE
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"Heterozygous females may manifest mild-to-moderate features of the disease"
GeneReviews confirms X-linked inheritance with variable carrier manifestation.
◆

Subtypes

4
Classic Pelizaeus-Merzbacher Disease
Most common form, onset in first months of life with nystagmus and head titubation, followed by progressive spasticity, ataxia, and cognitive impairment.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
Describes the clinical presentation and onset timing of classic PMD.
Connatal Pelizaeus-Merzbacher Disease
Severe form with neonatal onset, characterized by nystagmus, stridor, feeding difficulties, profound hypotonia progressing to spasticity, and severe developmental delay. Often fatal in childhood.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Connatal PMD presents earliest, in the neonatal period, and is the most aggressive of PMD phenotypes. Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"
Describes the severe neonatal presentation of connatal PMD.
Transitional Pelizaeus-Merzbacher Disease
Intermediate severity between classic and connatal forms. Includes spastic paraplegia type 2 (SPG2), which is of later onset with predominant lower extremity spasticity.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Transitional PMD combines clinical features of both the classic and connatal forms, and includes two principal phenotypes, spastic paraplegia and PLP1 null disease"
Describes transitional PMD and its relationship to SPG2.
PLP1 Null Syndrome
Caused by PLP1 null mutations. Milder CNS phenotype with peripheral neuropathy, as DM20 isoform partially compensates for PLP1 loss.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
Describes the PLP1 null phenotype with its characteristic peripheral neuropathy.
⚙

Pathophysiology

7
PLP1 Missense Mutation Causing Protein Misfolding
Missense mutations in PLP1 cause the mutant proteolipid protein to misfold in the endoplasmic reticulum of oligodendrocytes. Misfolded PLP1 accumulates and cannot be properly incorporated into myelin membranes.
oligodendrocyte link
PLP1 link
protein folding link
structural constituent of myelin sheath link
central nervous system white matter link
Show evidence (1 reference)
PMID:15627202 SUPPORT Human Clinical
"Distinct types of mutations, including point mutations and genomic duplications and deletions, have been identified as causes of PMD/SPG2 that act through different molecular mechanisms"
Reviews distinct molecular mechanisms for different PLP1 mutation types including misfolding pathways.
Unfolded Protein Response Activation in Oligodendrocytes
Accumulation of misfolded PLP1 in the endoplasmic reticulum activates the unfolded protein response (UPR) and ER stress pathways in oligodendrocytes.
oligodendrocyte link
response to endoplasmic reticulum stress link
central nervous system white matter link
Show evidence (2 references)
PMID:17115121 SUPPORT Human Clinical
"the wide range of mutations that can occur but also for the effects of PLP1 mutations on both cell autonomous and non-cell autonomous processes in myelinating cells"
Describes how PLP1 mutations affect cell-autonomous processes including ER stress in oligodendrocytes.
PMID:31585094 SUPPORT In Vitro
"Previous work showed involvement of unfolded protein response (UPR) and endoplasmic reticulum (ER) stress pathways"
Directly confirms UPR and ER stress pathway involvement in PLP1-mutant oligodendrocytes.
Oligodendrocyte Apoptosis
Sustained ER stress from misfolded PLP1 triggers apoptosis of oligodendrocytes, leading to loss of myelin-forming cells in the CNS.
oligodendrocyte link
apoptotic process link
central nervous system white matter link
Show evidence (2 references)
PMID:29478609 SUPPORT Human Clinical
"Accumulation in the ER leads to activation of the unfolded protein response (UPR) and consequent oligodendrocytic death"
Directly describes UPR-triggered oligodendrocyte death from ER-retained misfolded PLP1.
PMID:31585094 SUPPORT Model Organism
"reduced oligodendrocyte apoptosis and enabled myelin formation"
Iron chelation in jimpy mice reduced oligodendrocyte apoptosis, confirming apoptosis as a key cell death mechanism.
PLP1 Gene Duplication Causing Overexpression
PLP1 duplications, the most common cause of PMD (50-75% of cases), lead to overexpression of PLP1 protein.
oligodendrocyte link
PLP1 link
structural constituent of myelin sheath link
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"PLP gene duplications are the most common cause of Pelizaeus-Merzbacher disease"
Confirms PLP1 duplications as the most common mutation type.
Abnormal Cholesterol and Lipid Trafficking
Excess PLP1 from gene duplication causes sequestration of cholesterol in lysosomal compartments, resulting in abnormal trafficking of lipid rafts and sphingolipids, leading to oligodendrocyte injury and death.
oligodendrocyte link
lipid transport link
central nervous system white matter link
Show evidence (1 reference)
PMID:29478609 SUPPORT Model Organism
"Increased levels of PLP may lead to sequestration of cholesterol in the lysosomal compartments, resulting in abnormal cellular trafficking of lipid rafts and sphingolipids that are normally sorted out of the Golgi compartments, and this in turn may result in oligodendrocyte injury and early..."
Describes the mechanism by which PLP1 overexpression leads to oligodendrocyte dysfunction through lipid trafficking defects.
Defective CNS Myelination
Regardless of the specific PLP1 mutation type, the downstream consequence is a failure of normal CNS myelination. Oligodendrocytes either die before forming myelin or produce structurally abnormal myelin sheaths. MRI shows diffuse hypomyelination of the cerebral white matter.
oligodendrocyte link
CNS myelination link
cerebral white matter link
Show evidence (2 references)
PMID:27882623 SUPPORT Human Clinical
"all forms of the disease result in central hypomyelination, associated in most cases with early neurological dysfunction, progressive deterioration, and ultimately death"
Confirms that all forms of PMD share the feature of central hypomyelination.
PMID:29478609 SUPPORT Human Clinical
"There is a marked deficiency of myelin, particularly in deeper cerebral structures, but relative myelin preservation in areas surrounding blood vessels, providing the classic tigroid appearance of PMD histopathology"
Describes the characteristic histopathological pattern of myelin deficiency in PMD.
Iron-Dependent Oligodendrocyte Death (Ferroptosis)
PLP1-mutant oligodendrocytes exhibit hallmarks of ferroptosis including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron. Iron chelation with deferiprone rescues oligodendrocyte apoptosis and enables myelin formation in preclinical models, representing an additional death mechanism beyond ER stress-mediated apoptosis.
oligodendrocyte link
ferroptosis link
central nervous system white matter link
Show evidence (2 references)
PMID:31585094 SUPPORT In Vitro
"Mutant oligodendrocytes demonstrated key hallmarks of ferroptosis including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron"
iPSC-derived PLP1-mutant oligodendrocytes show ferroptosis hallmarks including lipid peroxidation and abnormal iron metabolism.
PMID:31585094 SUPPORT Model Organism
"systemic treatment of Plp1 mutant Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled myelin formation"
Iron chelation rescues oligodendrocyte death and enables myelination in the jimpy mouse model.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pelizaeus-Merzbacher Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

15
Eye 2
Nystagmus VERY_FREQUENT Nystagmus (HP:0000639)
Often the earliest sign, appearing in the first weeks to months of life. Typically pendular nystagmus.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"
Nystagmus is described as one of the cardinal features of prototypic PMD.
Optic Atrophy OCCASIONAL Optic atrophy (HP:0000648)
May develop later in disease course, particularly in connatal form.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"
Optic atrophy is described as a later-onset feature of classic PMD.
Musculoskeletal 3
Hypotonia VERY_FREQUENT Hypotonia (HP:0001252)
Early hypotonia that typically transitions to spasticity with age.
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"
GeneReviews confirms hypotonia as a typical early manifestation of PMD.
Progressive Spasticity VERY_FREQUENT Progressive spasticity (HP:0002191)
Develops after initial hypotonic phase, often becoming the predominant motor finding.
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"the findings progress to severe spasticity and ataxia"
GeneReviews confirms progressive spasticity as a major feature of PMD.
Scoliosis FREQUENT Scoliosis (HP:0002650)
Develops as a consequence of spasticity and immobility.
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"individuals with scoliosis benefit from proper wheelchair seating and physical therapy; surgery may be required for severe scoliosis"
GeneReviews describes scoliosis management as part of PMD care, confirming it as a recognized complication.
Nervous System 9
Ataxia FREQUENT Ataxia (HP:0001251)
Cerebellar ataxia contributing to motor impairment and gait difficulties.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
Cerebellar ataxia is listed among the neurological manifestations of PMD.
Intellectual Disability FREQUENT Intellectual disability (HP:0001249)
Variable severity; ranges from mild to severe depending on PMD form.
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"
Cognitive impairment is a core feature of PMD per GeneReviews.
Dysarthria FREQUENT Dysarthria (HP:0001260)
Speech difficulties due to spasticity and cerebellar involvement.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"spasticity of the lower extremities that can be isolated, or co-exist with varying degrees of cognitive impairment, nystagmus, ataxia, dysarthria and spastic urinary bladder"
Dysarthria is listed among the neurological features associated with PLP1-related disorders.
Head Titubation FREQUENT Head titubation (HP:0002599)
Involuntary rhythmic head movement, characteristic of classic PMD.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"
Head tremor (titubation) is described as a cardinal feature of prototypic PMD.
Leukodystrophy VERY_FREQUENT Leukodystrophy (HP:0002415)
MRI shows diffuse hypomyelination of cerebral white matter.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"MRI subsequently revealed overt hypomyelination, as reflected by the failure of PMD patients to develop the expected developmental increase in T1 and decrease in T2 signals characteristic of myelin maturation"
Describes the characteristic MRI finding of hypomyelination in PMD.
Delayed Motor Development VERY_FREQUENT Delayed gross motor development (HP:0002194)
Significant delays in achieving motor milestones; many patients never walk independently.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
Delayed or unachieved motor milestones are a core feature of classic PMD.
Choreoathetosis FREQUENT Choreoathetosis (HP:0001266)
Involuntary movements including choreoathetosis and dystonia.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
Choreoathetosis is listed among the neurological manifestations of PMD.
Seizures OCCASIONAL Seizure (HP:0001250)
Seizures may occur, particularly in connatal form. Typically responsive to antiepileptic agents.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"
Seizures occur but are uncommon and typically treatable in classic PMD.
Peripheral Neuropathy OCCASIONAL Demyelinating peripheral neuropathy (HP:0007108)
Primarily associated with PLP1 null mutations and deletions. Demyelinating type.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
Demyelinating peripheral neuropathy is characteristic of PLP1 null syndrome.
Respiratory 1
Laryngeal Stridor OCCASIONAL Stridor (HP:0010307)
Characteristic of connatal form. Due to laryngeal involvement.
Show evidence (1 reference)
PMID:29478609 SUPPORT Human Clinical
"Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"
Laryngeal stridor is a characteristic feature of connatal PMD.
🧬

Genetic Associations

1
PLP1 (Causative)
Show evidence (2 references)
PMID:15627202 SUPPORT Human Clinical
"Both PMD and SPG2 are caused by mutations in the proteolipid protein 1 (PLP1) gene, which encodes a major component of CNS myelin proteins"
Confirms PLP1 as the causative gene for PMD.
PMID:17115121 SUPPORT Human Clinical
"Pelizaeus-Merzbacher disease (PMD) and the allelic spastic paraplegia type 2 (SPG2) arise from mutations in the X-linked gene encoding myelin proteolipid protein (PLP)"
Confirms the genetic basis of PMD in PLP1 mutations.
💊

Treatments

4
Supportive Care
Action: supportive care MAXO:0000950
No cure exists for PMD. Treatment is supportive and includes physical therapy, occupational therapy, and management of spasticity with medications such as baclofen. Seizure management with antiepileptic drugs when needed.
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"routine management of spasticity including physical therapy, exercise, medications (baclofen, diazepam, tizanidine), orthotics, and surgery for joint contractures"
GeneReviews describes the multidisciplinary supportive care approach for PMD management.
Physical Therapy
Action: physical therapy MAXO:0000011
Rehabilitation to maintain mobility, prevent contractures, and optimize functional abilities.
Show evidence (1 reference)
PMID:20301361 SUPPORT Human Clinical
"physical and occupational therapy for ataxia with adaptive devices as needed"
GeneReviews recommends physical and occupational therapy as part of PMD management.
Stem Cell Transplantation (Investigational)
Action: neural stem cell transplantation Ontology label: cellular therapy MAXO:0000016
Neural stem cell and glial progenitor cell transplantation are being investigated as potential therapies for PMD, aiming to provide donor-derived oligodendrocytes capable of myelinating host axons.
Show evidence (1 reference)
PMID:27882623 SUPPORT Human Clinical
"PMD and similar hypomyelinating disorders are attractive therapeutic targets for neural stem cell and glial progenitor cell transplantation, efforts at which are now underway in a number of research centers"
Reviews the rationale and ongoing efforts for stem cell-based therapy in PMD.
PLP1 Antisense Oligonucleotide Therapy (Investigational)
Action: antisense oligonucleotide therapy Ontology label: antisense oligonucleotide inhibitor therapy MAXO:0001593
Antisense oligonucleotides (ASOs) targeting PLP1 mRNA to suppress expression have shown dramatic preclinical efficacy in the jimpy mouse model, fully restoring oligodendrocyte numbers, myelination, motor function, and lifespan. This approach exploits the observation that PLP1-null individuals have milder disease than those with gain-of-function mutations.
Show evidence (1 reference)
PMID:32610343 SUPPORT Model Organism
"Administration of a single dose of Plp1-targeting antisense oligonucleotides in postnatal jimpy mice fully restored oligodendrocyte numbers, increased myelination, improved motor performance, normalized respiratory function and extended lifespan up to an eight-month end point"
Landmark Nature study demonstrating that ASO-mediated PLP1 suppression rescues the jimpy mouse model of severe PMD.
🔬

Clinical Trials

1
NCT06150716 PHASE_I RECRUITING
Orbit study evaluating intrathecal ION356, a PLP1-targeting antisense oligonucleotide, in pediatric males with genetically confirmed PLP1 duplication PMD. Multiple ascending dose design with 48-week treatment and 109-week long-term extension.
Show evidence (1 reference)
clinicaltrials:NCT06150716 SUPPORT Human Clinical
"The primary purpose of this study is to evaluate the safety and tolerability of ION356"
Phase 1b trial of PLP1-lowering ASO therapy for PMD with PLP1 duplication.
{ }

Source YAML

click to show 
name: Pelizaeus-Merzbacher Disease
creation_date: "2026-03-14T12:00:00Z"
updated_date: "2026-04-07T00:12:52Z"
category: Genetic
parents:
- Leukodystrophy
- X-linked Recessive Disorder
disease_term:
  preferred_term: Pelizaeus-Merzbacher disease
  term:
    id: MONDO:0010714
    label: Pelizeaus-Merzbacher spectrum disorder
description: >
  Pelizaeus-Merzbacher disease (PMD) is an X-linked recessive hypomyelinating
  leukodystrophy caused by mutations in the PLP1 gene encoding proteolipid protein 1,
  the major structural protein of central nervous system myelin. PLP1 mutations lead to
  defective myelination through various mechanisms including protein misfolding,
  endoplasmic reticulum stress, oligodendrocyte apoptosis, and gene dosage effects.
  Clinical features include nystagmus, hypotonia, spasticity, ataxia, intellectual
  disability, and progressive motor deterioration. PMD is classified into connatal
  (severe), classic, and transitional forms based on age of onset and severity.
prevalence:
- population: Global
  percentage: 1 in 200,000 to 500,000
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "their diagnosed prevalence ranges from 1:200,000–1:500,000 in the US, with international incidence ranging from 1:90,000–1:750,000 live births"
    explanation: Provides prevalence estimates for PMD from US and international data.
  notes: >
    PMD predominantly affects males due to X-linked recessive inheritance.
    Carrier females may occasionally show mild symptoms.
progression:
- phase: Onset
  age_range: Infancy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
    explanation: Describes onset timing and initial features of classic PMD.
  notes: >
    Classic PMD presents in first months of life with nystagmus and hypotonia.
    Connatal form presents at birth with more severe symptoms including stridor.
- phase: Progression
  age_range: Childhood-Adulthood
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Appendicular spasticity and involuntary movements both follow this initial presentation"
    explanation: Describes the progressive nature of motor deterioration in classic PMD.
  notes: >
    Progressive spasticity, ataxia, and cognitive decline. Life span varies from
    adolescence to young adulthood in classic PMD; connatal form often fatal in childhood.
inheritance:
- name: X-linked Recessive
  description: >
    The PLP1 gene is located on chromosome Xq22.2. Most affected individuals are
    males. Carrier females may show mild neurological signs.
  expressivity: VARIABLE
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygous females may manifest mild-to-moderate features of the disease"
    explanation: GeneReviews confirms X-linked inheritance with variable carrier manifestation.
has_subtypes:
- name: Classic Pelizaeus-Merzbacher Disease
  description: >
    Most common form, onset in first months of life with nystagmus and head titubation,
    followed by progressive spasticity, ataxia, and cognitive impairment.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
    explanation: Describes the clinical presentation and onset timing of classic PMD.
- name: Connatal Pelizaeus-Merzbacher Disease
  description: >
    Severe form with neonatal onset, characterized by nystagmus, stridor, feeding
    difficulties, profound hypotonia progressing to spasticity, and severe
    developmental delay. Often fatal in childhood.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Connatal PMD presents earliest, in the neonatal period, and is the most aggressive of PMD phenotypes. Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"
    explanation: Describes the severe neonatal presentation of connatal PMD.
- name: Transitional Pelizaeus-Merzbacher Disease
  description: >
    Intermediate severity between classic and connatal forms. Includes spastic
    paraplegia type 2 (SPG2), which is of later onset with predominant lower
    extremity spasticity.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transitional PMD combines clinical features of both the classic and connatal forms, and includes two principal phenotypes, spastic paraplegia and PLP1 null disease"
    explanation: Describes transitional PMD and its relationship to SPG2.
- name: PLP1 Null Syndrome
  description: >
    Caused by PLP1 null mutations. Milder CNS phenotype with peripheral neuropathy,
    as DM20 isoform partially compensates for PLP1 loss.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
    explanation: Describes the PLP1 null phenotype with its characteristic peripheral neuropathy.
pathophysiology:
- name: PLP1 Missense Mutation Causing Protein Misfolding
  description: >
    Missense mutations in PLP1 cause the mutant proteolipid protein to misfold in the
    endoplasmic reticulum of oligodendrocytes. Misfolded PLP1 accumulates and cannot
    be properly incorporated into myelin membranes.
  genes:
  - preferred_term: PLP1
    term:
      id: hgnc:9078
      label: PLP1
  molecular_functions:
  - preferred_term: structural constituent of myelin sheath
    term:
      id: GO:0019911
      label: structural constituent of myelin sheath
  downstream:
  - target: Unfolded Protein Response Activation in Oligodendrocytes
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:15627202
    reference_title: "PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Distinct types of mutations, including point mutations and genomic duplications and deletions, have been identified as causes of PMD/SPG2 that act through different molecular mechanisms"
    explanation: Reviews distinct molecular mechanisms for different PLP1 mutation types including misfolding pathways.
- name: Unfolded Protein Response Activation in Oligodendrocytes
  description: >
    Accumulation of misfolded PLP1 in the endoplasmic reticulum activates the
    unfolded protein response (UPR) and ER stress pathways in oligodendrocytes.
  downstream:
  - target: Oligodendrocyte Apoptosis
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:17115121
    reference_title: "Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the wide range of mutations that can occur but also for the effects of PLP1 mutations on both cell autonomous and non-cell autonomous processes in myelinating cells"
    explanation: Describes how PLP1 mutations affect cell-autonomous processes including ER stress in oligodendrocytes.
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Previous work showed involvement of unfolded protein response (UPR) and endoplasmic reticulum (ER) stress pathways"
    explanation: Directly confirms UPR and ER stress pathway involvement in PLP1-mutant oligodendrocytes.
- name: Oligodendrocyte Apoptosis
  description: >
    Sustained ER stress from misfolded PLP1 triggers apoptosis of oligodendrocytes,
    leading to loss of myelin-forming cells in the CNS.
  downstream:
  - target: Defective CNS Myelination
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accumulation in the ER leads to activation of the unfolded protein response (UPR) and consequent oligodendrocytic death"
    explanation: Directly describes UPR-triggered oligodendrocyte death from ER-retained misfolded PLP1.
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "reduced oligodendrocyte apoptosis and enabled myelin formation"
    explanation: Iron chelation in jimpy mice reduced oligodendrocyte apoptosis, confirming apoptosis as a key cell death mechanism.
- name: PLP1 Gene Duplication Causing Overexpression
  description: >
    PLP1 duplications, the most common cause of PMD (50-75% of cases), lead to
    overexpression of PLP1 protein.
  genes:
  - preferred_term: PLP1
    term:
      id: hgnc:9078
      label: PLP1
  molecular_functions:
  - preferred_term: structural constituent of myelin sheath
    term:
      id: GO:0019911
      label: structural constituent of myelin sheath
  downstream:
  - target: Abnormal Cholesterol and Lipid Trafficking
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PLP gene duplications are the most common cause of Pelizaeus-Merzbacher disease"
    explanation: Confirms PLP1 duplications as the most common mutation type.
- name: Abnormal Cholesterol and Lipid Trafficking
  description: >
    Excess PLP1 from gene duplication causes sequestration of cholesterol in
    lysosomal compartments, resulting in abnormal trafficking of lipid rafts
    and sphingolipids, leading to oligodendrocyte injury and death.
  downstream:
  - target: Defective CNS Myelination
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: lipid transport
    term:
      id: GO:0006869
      label: lipid transport
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increased levels of PLP may lead to sequestration of cholesterol in the lysosomal compartments, resulting in abnormal cellular trafficking of lipid rafts and sphingolipids that are normally sorted out of the Golgi compartments, and this in turn may result in oligodendrocyte injury and early oligodendroglial death"
    explanation: Describes the mechanism by which PLP1 overexpression leads to oligodendrocyte dysfunction through lipid trafficking defects.
- name: Defective CNS Myelination
  description: >
    Regardless of the specific PLP1 mutation type, the downstream consequence is a
    failure of normal CNS myelination. Oligodendrocytes either die before forming
    myelin or produce structurally abnormal myelin sheaths. MRI shows diffuse
    hypomyelination of the cerebral white matter.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: CNS myelination
    term:
      id: GO:0022010
      label: central nervous system myelination
  locations:
  - preferred_term: cerebral white matter
    term:
      id: UBERON:0002437
      label: cerebral hemisphere white matter
  evidence:
  - reference: PMID:27882623
    reference_title: "Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all forms of the disease result in central hypomyelination, associated in most cases with early neurological dysfunction, progressive deterioration, and ultimately death"
    explanation: Confirms that all forms of PMD share the feature of central hypomyelination.
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is a marked deficiency of myelin, particularly in deeper cerebral structures, but relative myelin preservation in areas surrounding blood vessels, providing the classic tigroid appearance of PMD histopathology"
    explanation: Describes the characteristic histopathological pattern of myelin deficiency in PMD.
- name: Iron-Dependent Oligodendrocyte Death (Ferroptosis)
  description: >
    PLP1-mutant oligodendrocytes exhibit hallmarks of ferroptosis including lipid
    peroxidation, abnormal iron metabolism, and hypersensitivity to free iron.
    Iron chelation with deferiprone rescues oligodendrocyte apoptosis and enables
    myelin formation in preclinical models, representing an additional death
    mechanism beyond ER stress-mediated apoptosis.
  downstream:
  - target: Defective CNS Myelination
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
  locations:
  - preferred_term: central nervous system white matter
    term:
      id: UBERON:0003544
      label: brain white matter
  evidence:
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mutant oligodendrocytes demonstrated key hallmarks of ferroptosis including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron"
    explanation: iPSC-derived PLP1-mutant oligodendrocytes show ferroptosis hallmarks including lipid peroxidation and abnormal iron metabolism.
  - reference: PMID:31585094
    reference_title: "Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "systemic treatment of Plp1 mutant Jimpy mice with deferiprone, a small molecule iron chelator, reduced oligodendrocyte apoptosis and enabled myelin formation"
    explanation: Iron chelation rescues oligodendrocyte death and enables myelination in the jimpy mouse model.
phenotypes:
- name: Nystagmus
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Often the earliest sign, appearing in the first weeks to months of life. Typically pendular nystagmus.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"
    explanation: Nystagmus is described as one of the cardinal features of prototypic PMD.
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Early hypotonia that typically transitions to spasticity with age.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"
    explanation: GeneReviews confirms hypotonia as a typical early manifestation of PMD.
- name: Progressive Spasticity
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Develops after initial hypotonic phase, often becoming the predominant motor finding.
  phenotype_term:
    preferred_term: Progressive spasticity
    term:
      id: HP:0002191
      label: Progressive spasticity
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the findings progress to severe spasticity and ataxia"
    explanation: GeneReviews confirms progressive spasticity as a major feature of PMD.
- name: Ataxia
  category: Neurological
  frequency: FREQUENT
  notes: Cerebellar ataxia contributing to motor impairment and gait difficulties.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
    explanation: Cerebellar ataxia is listed among the neurological manifestations of PMD.
- name: Intellectual Disability
  category: Neurological
  frequency: FREQUENT
  notes: Variable severity; ranges from mild to severe depending on PMD form.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment"
    explanation: Cognitive impairment is a core feature of PMD per GeneReviews.
- name: Dysarthria
  category: Neurological
  frequency: FREQUENT
  notes: Speech difficulties due to spasticity and cerebellar involvement.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity of the lower extremities that can be isolated, or co-exist with varying degrees of cognitive impairment, nystagmus, ataxia, dysarthria and spastic urinary bladder"
    explanation: Dysarthria is listed among the neurological features associated with PLP1-related disorders.
- name: Head Titubation
  category: Neurological
  frequency: FREQUENT
  notes: Involuntary rhythmic head movement, characteristic of classic PMD.
  phenotype_term:
    preferred_term: Head titubation
    term:
      id: HP:0002599
      label: Head titubation
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it is characterized by pendular nystagmus, head tremor, and systemic hypotonia"
    explanation: Head tremor (titubation) is described as a cardinal feature of prototypic PMD.
- name: Leukodystrophy
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: MRI shows diffuse hypomyelination of cerebral white matter.
  phenotype_term:
    preferred_term: Leukodystrophy
    term:
      id: HP:0002415
      label: Leukodystrophy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI subsequently revealed overt hypomyelination, as reflected by the failure of PMD patients to develop the expected developmental increase in T1 and decrease in T2 signals characteristic of myelin maturation"
    explanation: Describes the characteristic MRI finding of hypomyelination in PMD.
- name: Delayed Motor Development
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Significant delays in achieving motor milestones; many patients never walk independently.
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Classic PMD presents before the first year of age, with nystagmus, slowly acquired or unachieved motor milestones, and significant axial hypotonia"
    explanation: Delayed or unachieved motor milestones are a core feature of classic PMD.
- name: Choreoathetosis
  category: Neurological
  frequency: FREQUENT
  notes: Involuntary movements including choreoathetosis and dystonia.
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "affected patients manifest some combination of mental retardation, choreoathetosis, dystonia, cerebellar ataxia and long tract signs"
    explanation: Choreoathetosis is listed among the neurological manifestations of PMD.
- name: Seizures
  category: Neurological
  frequency: OCCASIONAL
  notes: Seizures may occur, particularly in connatal form. Typically responsive to antiepileptic agents.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"
    explanation: Seizures occur but are uncommon and typically treatable in classic PMD.
- name: Optic Atrophy
  category: Ophthalmological
  frequency: OCCASIONAL
  notes: May develop later in disease course, particularly in connatal form.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Optic atrophy and seizures may occur later in the course, although seizures are uncommon, and typically treatable"
    explanation: Optic atrophy is described as a later-onset feature of classic PMD.
- name: Laryngeal Stridor
  category: Respiratory
  frequency: OCCASIONAL
  notes: Characteristic of connatal form. Due to laryngeal involvement.
  phenotype_term:
    preferred_term: Laryngeal stridor
    term:
      id: HP:0010307
      label: Stridor
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Babies with connatal PMD manifest extrapyramidal signs, laryngeal stridor, feeding difficulties and optic atrophy"
    explanation: Laryngeal stridor is a characteristic feature of connatal PMD.
- name: Scoliosis
  category: Musculoskeletal
  frequency: FREQUENT
  notes: Develops as a consequence of spasticity and immobility.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individuals with scoliosis benefit from proper wheelchair seating and physical therapy; surgery may be required for severe scoliosis"
    explanation: GeneReviews describes scoliosis management as part of PMD care, confirming it as a recognized complication.
- name: Peripheral Neuropathy
  category: Neurological
  frequency: OCCASIONAL
  notes: Primarily associated with PLP1 null mutations and deletions. Demyelinating type.
  phenotype_term:
    preferred_term: Demyelinating peripheral neuropathy
    term:
      id: HP:0007108
      label: Demyelinating peripheral neuropathy
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PLP1 null phenotype represents another syndrome later described by Garbern and colleagues, and is characterized by complicated spastic paraplegia, with mild to moderate demyelinating peripheral neuropathy and axonal injury"
    explanation: Demyelinating peripheral neuropathy is characteristic of PLP1 null syndrome.
genetic:
- name: PLP1
  association: Causative
  gene_term:
    preferred_term: PLP1
    term:
      id: hgnc:9086
      label: PLP1
  notes: >
    PMD is caused by mutations in the PLP1 gene (Xq22.2), which encodes proteolipid
    protein 1, the major protein component of CNS myelin. PLP1 duplications account
    for 50-75% of cases, point mutations for about 20%, and deletions for less than 5%.
  variants:
  - name: PLP1 duplication
    description: >
      Genomic duplication of the PLP1 locus, the most common mutation type (50-75%
      of cases). Leads to PLP1 overexpression and classic PMD phenotype.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PLP gene duplications are the most common cause of Pelizaeus-Merzbacher disease"
      explanation: Confirms PLP1 duplications as the predominant cause of PMD.
  - name: PLP1 point mutations
    description: >
      Missense mutations causing protein misfolding. Severity depends on specific
      residue; some cause severe connatal form, others milder phenotypes.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Point mutations account for another 20% of cases, and are associated with highly variable phenotypes; these can vary from clinically mild to severe connatal forms"
      explanation: Describes the prevalence and clinical variability of PLP1 point mutations.
  - name: PLP1 deletion
    description: >
      Complete loss of PLP1 expression. Paradoxically causes milder CNS disease
      but with added peripheral neuropathy, as the DM20 isoform partially
      compensates in the CNS.
    evidence:
    - reference: PMID:29478609
      reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PLP1 deletions are less common, accounting for <5% of identified cases; paradoxically, these are associated with milder phenotypes"
      explanation: Confirms that PLP1 deletions cause a paradoxically milder phenotype.
  evidence:
  - reference: PMID:15627202
    reference_title: "PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both PMD and SPG2 are caused by mutations in the proteolipid protein 1 (PLP1) gene, which encodes a major component of CNS myelin proteins"
    explanation: Confirms PLP1 as the causative gene for PMD.
  - reference: PMID:17115121
    reference_title: "Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher disease (PMD) and the allelic spastic paraplegia type 2 (SPG2) arise from mutations in the X-linked gene encoding myelin proteolipid protein (PLP)"
    explanation: Confirms the genetic basis of PMD in PLP1 mutations.
treatments:
- name: Supportive Care
  description: >
    No cure exists for PMD. Treatment is supportive and includes physical therapy,
    occupational therapy, and management of spasticity with medications such as
    baclofen. Seizure management with antiepileptic drugs when needed.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "routine management of spasticity including physical therapy, exercise, medications (baclofen, diazepam, tizanidine), orthotics, and surgery for joint contractures"
    explanation: GeneReviews describes the multidisciplinary supportive care approach for PMD management.
- name: Physical Therapy
  description: >
    Rehabilitation to maintain mobility, prevent contractures, and optimize
    functional abilities.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "physical and occupational therapy for ataxia with adaptive devices as needed"
    explanation: GeneReviews recommends physical and occupational therapy as part of PMD management.
- name: Stem Cell Transplantation (Investigational)
  description: >
    Neural stem cell and glial progenitor cell transplantation are being investigated
    as potential therapies for PMD, aiming to provide donor-derived oligodendrocytes
    capable of myelinating host axons.
  treatment_term:
    preferred_term: neural stem cell transplantation
    term:
      id: MAXO:0000016
      label: cellular therapy
  evidence:
  - reference: PMID:27882623
    reference_title: "Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMD and similar hypomyelinating disorders are attractive therapeutic targets for neural stem cell and glial progenitor cell transplantation, efforts at which are now underway in a number of research centers"
    explanation: Reviews the rationale and ongoing efforts for stem cell-based therapy in PMD.
- name: PLP1 Antisense Oligonucleotide Therapy (Investigational)
  description: >
    Antisense oligonucleotides (ASOs) targeting PLP1 mRNA to suppress expression
    have shown dramatic preclinical efficacy in the jimpy mouse model, fully
    restoring oligodendrocyte numbers, myelination, motor function, and lifespan.
    This approach exploits the observation that PLP1-null individuals have milder
    disease than those with gain-of-function mutations.
  treatment_term:
    preferred_term: antisense oligonucleotide therapy
    term:
      id: MAXO:0001593
      label: antisense oligonucleotide inhibitor therapy
  evidence:
  - reference: PMID:32610343
    reference_title: "Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Administration of a single dose of Plp1-targeting antisense oligonucleotides in postnatal jimpy mice fully restored oligodendrocyte numbers, increased myelination, improved motor performance, normalized respiratory function and extended lifespan up to an eight-month end point"
    explanation: Landmark Nature study demonstrating that ASO-mediated PLP1 suppression rescues the jimpy mouse model of severe PMD.
diagnosis:
- name: Brain MRI
  description: >
    MRI reveals diffuse hypomyelination with failure to develop normal T1 and T2
    signal maturation patterns. The hallmark is absence of normal myelination
    progression on serial imaging.
  evidence:
  - reference: PMID:29478609
    reference_title: "Neurogenetics of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI subsequently revealed overt hypomyelination, as reflected by the failure of PMD patients to develop the expected developmental increase in T1 and decrease in T2 signals characteristic of myelin maturation"
    explanation: Describes the characteristic MRI pattern used to diagnose PMD.
- name: PLP1 Molecular Genetic Testing
  description: >
    Diagnosis is confirmed by identification of a hemizygous pathogenic variant
    in PLP1 including duplications, point mutations, or deletions. Testing
    methods include MLPA, array CGH, and sequencing.
  evidence:
  - reference: PMID:20301361
    reference_title: "PLP1-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of a PLP1-related disorder is established in a male proband by identification of a hemizygous pathogenic variant involving PLP1"
    explanation: GeneReviews confirms that molecular genetic testing of PLP1 establishes the diagnosis.
animal_models:
- species: Mouse
  genotype: Plp1jp (jimpy)
  description: >
    The jimpy mouse carries a point mutation in Plp1, modeling severe connatal PMD.
    Characterized by extensive oligodendrocyte loss, severe hypomyelination,
    seizures, tremor, and early death at 3-4 weeks of age. Used extensively for
    preclinical therapeutic studies including ASO and CRISPR approaches.
  associated_phenotypes:
  - Severe hypomyelination
  - Oligodendrocyte apoptosis
  - Tremor
  - Seizures
  - Early lethality
  evidence:
  - reference: PMID:32610343
    reference_title: "Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "using CRISPR-Cas9 to suppress Plp1 expression in the jimpy (Plp1jp) point-mutation mouse model of severe PMD, increased myelination and restored nerve conduction velocity, motor function and lifespan of the mice to wild-type levels"
    explanation: Describes the jimpy mouse model and its rescue through PLP1 suppression.
- species: Mouse
  genotype: Plp1 transgenic (overexpression)
  description: >
    Transgenic mice overexpressing Plp1 model the PLP1 duplication form of PMD.
    Show severe demyelination, oligodendrocyte death, and motor dysfunction
    proportional to the level of PLP1 overexpression.
  associated_phenotypes:
  - Demyelination
  - Oligodendrocyte maturation arrest
  - Motor dysfunction
  evidence:
  - reference: PMID:24680886
    reference_title: "Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We used a Plp1 transgenic PMD mouse model to test the therapeutic effect of Lonaprisan, an antagonist of the nuclear progesterone receptor, in lowering Plp1 mRNA overexpression"
    explanation: Describes the Plp1 transgenic mouse model used to study duplication-based PMD.
  - reference: PMID:21401588
    reference_title: "Axon-glial interaction in the CNS: what we have learned from mouse models of Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Animal models of these diseases, particularly models lacking or overexpressing Plp1, have shed light on the interplay between axons and oligodendrocytes, and how one component influences the other"
    explanation: Reviews mouse models of PMD including overexpression models and their contributions to understanding axon-glial interactions.
clinical_trials:
- name: NCT06150716
  phase: PHASE_I
  status: RECRUITING
  description: >
    Orbit study evaluating intrathecal ION356, a PLP1-targeting antisense
    oligonucleotide, in pediatric males with genetically confirmed PLP1
    duplication PMD. Multiple ascending dose design with 48-week treatment
    and 109-week long-term extension.
  evidence:
  - reference: clinicaltrials:NCT06150716
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary purpose of this study is to evaluate the safety and tolerability of ION356"
    explanation: Phase 1b trial of PLP1-lowering ASO therapy for PMD with PLP1 duplication.
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: demyelinating disease
  - classification_value: hereditary disease
datasets: []